Evidence map›Paper›PMID 40390185›Full record

ArticleStatistics in medicine2025

TODO: A Triple-Outcome Double-Criterion Optimal Design for Dose Monitoring-and-Optimization in Multi-Dose Randomized Trials.

Jingyi Zhang, Heng Zhou, Nolan A Wages, Zifang Guo, Fang Liu, Thomas Jemielita, Fangrong Yan, Ruitao Lin

Abstract read
In one paragraph

Article in Statistics in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jingyi ZhangResearch Center of Biostatistics and Computational Pharmacy, China Pharmaceutical University, Nanjing, China.
Heng ZhouBiostatistics and Research Decision Sciences, Merck & Co., Inc, Rahway, New Jersey, USA.
Nolan A WagesDepartment of Biostatistics, Virginia Commonwealth University, Richmond, Virginia, USA.
Zifang GuoBiostatistics and Research Decision Sciences, Merck & Co., Inc, Rahway, New Jersey, USA.
Fang LiuBiostatistics and Research Decision Sciences, Merck & Co., Inc, Rahway, New Jersey, USA.
Thomas JemielitaBiostatistics and Research Decision Sciences, Merck & Co., Inc, Rahway, New Jersey, USA.
Fangrong YanResearch Center of Biostatistics and Computational Pharmacy, China Pharmaceutical University, Nanjing, China.ORCID https://orcid.org/0000-0003-3347-5021
Ruitao LinDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0003-2244-131X

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
The University of Texas MD Anderson Cancer Center SPORE in MelanomaP50CA221703 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DAVIES, MICHAEL · 2019 to 2023
$10.3M
Bayesian Methods for Complex Precision Biotherapy Trials in OncologyR01CA261978 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LIN, RUITAO, THALL, PETER F · 2021 to 2024
$1.4M
Novel designs for multi-arm multi-dose multi-stage platform trialsR21LM014699 · NLM · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Ruitao Lin · 2025 to 2026
$405k
NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA221703NCI NIH HHS R01 CA261978NLM NIH HHS R21 LM014699
6 · The paper itself

Abstract

Detecting the efficacy signal and determining the optimal dose are critical steps to increase the probability of success and expedite the drug development in cancer treatment. After identifying a safe dose range through phase I studies, conducting a multidose randomized trial becomes an effective approach to achieve this objective. However, there have been limited formal statistical designs for such multidose trials, and dose selection in practice is often ad hoc, relying on descriptive statistics. We propose a Bayesian optimal two-stage design to facilitate rigorous dose monitoring and optimization. Utilizing a flexible Bayesian dynamic linear model for the dose-response relationship, we employ dual criteria to assess dose admissibility and desirability. Additionally, we introduce a triple-outcome trial decision procedure to consider dose selection beyond clinical factors. Under the proposed model and decision rules, we develop a systematic calibration algorithm to determine the sample size and Bayesian posterior probability cutoffs to optimize specific design operating characteristics. Furthermore, we demonstrate how to concurrently assess toxicity and efficacy within the proposed framework using a utility-based risk-benefit trade-off. To validate the effectiveness of our design, we conduct extensive simulation studies across a variety of scenarios, demonstrating its robust operating characteristics.

Indexed as

Antineoplastic AgentsDose-Response Relationship, DrugRandomized Controlled Trials as TopicResearch DesignAlgorithmsBayes TheoremClinical Trials, Phase I as TopicComputer SimulationHumansLinear ModelsModels, StatisticalNeoplasmsSample SizeAntineoplastic Agentscohort expansiondose monitoringdose optimizationdynamic linear modelnoninferioritytriple‐outcome decision

Identifiers

PMID40390185
PMCPMC12089520

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.